Study in patients with moderate to severe psoriasis to assess efficacy and safety of secukinumab

Update Il y a 4 ans
Reference: EUCTR2014-001974-32

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To demonstrate that 300 mg secukinumab administered every 2 weeks is superior in achieving PASI 90 at week 32 compared to 300 mg secukinumab every 4 weeks in patients who after treatment with the standard dose had less than almost clear skin (PASI≥75 to PASI<90) at week 16.


Inclusion criteria

  • chronic moderate to severe plaque type psoriasis

Links